Business Wire

CA-ANDERSEN-GLOBAL

11.11.2020 22:36:10 CET | Business Wire | Pressemeddelelse

Del
Andersen styrker platform i Mellemøsten

Andersen fortsætter med at styrke sin problemfri service til kunder rundt om i verden, og deres brand følger efter, når Andersen Globals medlemsfirmaer i Mellemøsten nu opererer under brandet ”Andersen”. Meddelelsen kommer i forbindelse med optagelsen af brandet ”Andersen” blandt europæiske og latinamerikanske medlemsfirmaer tidligere i år.

Andersen Global-medlemsfirmaer, der tidligere opererede under brands ”Andersen Tax” og ”Andersen Tax & Legal” i Egypten, Jordan og Kuwait går nu over til det fælles brand ”Andersen”. Derudover byder Andersen velkommen til medlemsfirmaet Alrikaz i kongeriet Saudi-Arabien (KSA), som også tager Andersen-brandet til sig. Optagelsen af det fælles brand i regionen reflekterer på bedste vis det fulde omfang af den globale service, som Andersen-medlemsfirmaer tilbyder deres kunder, inklusive juridisk service i 16 lande, hvoraf to er i Mellemøsten.

Udover sine medlemsfirmaer i Egypten, Jordan, Kuwait og KSA er Andersen Global også tilstede i Mellemøsten i Bahrain, Libanon, Oman, Palæstina, Qatar og De Forenede Arabiske Emirater via samarbejdsfirmaer, med planer for fremtidig ekspansion.

”Vores optagelse af et fælles globalt brand viser hvor langt vi er kommet som organisation, og hvor vi er på vej hen”, sagde Mark Vorsatz, Andersen Global Chairman og Andersen CEO. ”Vi er engageret i at skabe en benchmarkingorganisation, som sætter den globale standard for den bedste uafhængige og synergistiske service i sin klasse. Vores fælles brand kendetegner vores problemfri service og delte centrale værdier rundt om i verden.”

Grundlaget for Andersens globale platform går helt tilbage til 2002, hvor 23 tidligere Arthur Andersen-partnere oprettede et firma, der kun beskæftigede sig med skat, WTAS LLC, som efterfulgtes af Andersen Global (tidligere WTAS Global) i 2014. Det samme år tog det grundlæggende amerikanske medlemsfirma brandet ”Andersen Tax” til sig, efterfulgt af medlemsfirmaer i Latinamerika, Europa og Afrika. Andersen Tax og Andersen Tax & Legal debuterede i Mellemøsten i 2017, og regionen er siden blevet udvidet til i dag at omfatte mere end 20 lokationer, 500 medarbejdere indenfor skat og jura, og næsten 100 partnere.

”Mellemøsten er et marked under udvikling, og skattebranchen er i fremgang, med særlig fokus på diversificering af økonomier,” sagde Fouad Al Hourani, Co-Regional Managing Director i Mellemøsten. ”Ved at tilbyde omfattende, problemfrie servicer, inklusive skat og jura, har vi lagt et solidt grundlag, og skabt en konkurrencedygtig platform for vores organisation i regionen.”

Lena Hamdi, Co-Regional Managing Director i Mellemøsten, tilføjer: ”Vores medlemsfirmaers servicetilbud gør os i stand til at opfylde vores kunders behov uanset grænser. Et fælles brand er en milepæl for vores organisation, og vi ser frem til dette næste trin af regionens udvikling.”

I løbet af det næste år fortsætter medlemsfirmaer i Afrika, Canada og Israel med at optage det fælles Andersen-brand, mens Andersen Global fortsætter med at udvide på vigtige markeder, herunder Caribien, Latinamerika, Afrika og Mellemøsten.

Andersen Global er en international sammenslutning af juridisk adskilte, uafhængige medlemsfirmaer bestående af skatte- og juraeksperter fra hele verden. Siden oprettelsen i 2013 af det amerikanske medlemsfirma Andersen Tax LLC har Andersen Global nu over 6.000 eksperter globalt og er repræsenteret på over 214 lokaliteter via sine medlems- og samarbejdsfirmaer.

Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye